CD4 T Cells Induce a Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology

Kritika Mittal, Ekaterina Eremenko, Omer Berner, ..., Anna Nemirovsky, Ivo Spiegel, Alon Monsonego
alomon@bgu.ac.il

HIGHLIGHTS
ICV-injected Aβ-Th1 T cells elevate MHCII+ microglial cells around plaques
T cells undergo stimulation by microglia and facilitate amyloid clearance
Microglia-T cell interactions orchestrate immune mechanisms regulating AD pathology

Mittal et al., iScience 16, 298–311
June 28, 2019 © 2019 The Authors.
https://doi.org/10.1016/j.isci.2019.05.039
CD4 T Cells Induce A Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology

Kritika Mittal,1,3 Ekaterina Eremenko,1,3 Omer Berner,1 Yehezqel Elyahu,1 Itai Strominger,1 Daniella Apelblat,2 Anna Nemirovsky,1 Ivo Spiegel,2 and Alon Monsonego1,4,*

SUMMARY

Microglia play a key role in innate immunity in Alzheimer disease (AD), but their role as antigen-presenting cells is as yet unclear. Here we found that amyloid β peptide (Aβ)-specific T helper 1 (Aβ-Th1 cells) T cells polarized to secrete interferon-γ and intracerebroventricularly (ICV) injected to the 5XFAD mouse model of AD induced the differentiation of major histocompatibility complex class II (MHCII)+ microglia with distinct morphology and enhanced plaque clearance capacity than MHCII− microglia. Notably, 5XFAD mice lacking MHCII exhibited an enhanced amyloid pathology in the brain along with exacerbated innate inflammation and reduced phagocytic capacity. Using a bone marrow chimera mouse model, we showed that infiltrating macrophages did not differentiate to MHCII+ cells following ICV injection of Aβ-Th1 cells and did not support T cell-mediated amyloid clearance. Overall, we demonstrate that CD4 T cells induce a P2ry12+ MHCII+ subset of microglia, which play a key role in T cell-mediated effector functions that abrogate AD-like pathology.

INTRODUCTION

Alzheimer disease (AD) is a neurodegenerative disease and the primary cause of dementia (Giannakopoulos et al., 2003). The robust synaptic and neuronal loss in the hippocampal and cortical areas of the brain is accompanied by the accumulation of misfolded proteins, such as the amyloid β peptide (Aβ), and by neurofibrillary tangles in affected sites in the parenchyma and vasculature of the brain (Iqbal et al., 2016; Orr et al., 2017; Selkoe and Hardy, 2016). Together, these changes appear to be neurotoxic and cause chronic innate inflammation (Andreason et al., 2016; Heneka et al., 2015; Van Eldik et al., 2016; Wyss-Coray and Rogers, 2012; Zotova et al., 2010). Innate inflammation in the brain is characterized primarily as a glial activation process, in which both astrocytes and microglia accumulate around amyloid plaques and, thereby, exhibit activated and dysfunctional phenotypes that further increase neurotoxicity (Block et al., 2007; Serrano-Pozo et al., 2011). Whether adaptive immunity mediated by CD4 T cells plays a key role in the inflammatory process in the brain and can be therapeutically used to abrogate the disease is still a matter of debate.

CD4 T cells play a key role in immune regulation and can substantially impact neuroinflammatory processes in the central nervous system (CNS), such as those observed in multiple sclerosis (Hoppmann et al., 2015; Peeters et al., 2017), amyotrophic lateral sclerosis (Chiu et al., 2008), and Parkinson disease (Mosley and Gendelman, 2017; Sulzer et al., 2017). The infiltration of CD4 T cells into the brain can be destructive (Anderson et al., 2014; Walsh et al., 2014), but, depending on the neuroinflammatory process and the phenotypes of these T cells, they can also limit neuronal damage caused by infection (Russo and McGavern, 2015), stroke (Liesz et al., 2009), or neurodegenerative diseases (Bryson and Lynch, 2016). Studies in people with AD (Monsonego et al., 2003; Parachikova et al., 2007; Togo et al., 2002; Zota et al., 2009) and in mouse models of the disease (Baek et al., 2016; Baruch et al., 2015, 2016; Dansokho et al., 2016) suggest that certain CD4 lymphocyte subsets can markedly impact the disease process. We previously showed that whereas peripheral Aβ immunization can cause meningoencephalitis (Monsonego et al., 2006), intracerebroventricularly (ICV)-injected T helper 1 (Th1) T cells can target Aβ plaques in the brain parenchyma and, thereby, locally impact the neuroinflammatory niche to enhance Aβ clearance and reduce innate inflammation, with no evidence of neurotoxic inflammation (Fisher et al., 2014). Notably, these effects of the T cells were mostly brain antigen specific and were not observed to the same extent with ICV-injected ovalbumin (OVA)-specific Th1 T cells (Fisher et al., 2014). Overall, these studies demonstrate that peripheral CD4 T cells can migrate into the brain and locally exert effector functions, which impact the progression of AD-like pathology.
AD, possibly due to local interactions with major histocompatibility complex class II (MHCII)-expressing cells.

The expression of MHCII in the brain is low under homeostatic conditions, whereas it can be upregulated in microglia following brain infection or trauma, or over the course of neurodegenerative diseases (McGeer et al., 1987; Schetters et al., 2017; Streit et al., 1999). In people with AD, MHCII expression was found to be upregulated by microglia at sites of Aβ plaques (McGeer et al., 1987; Parachikova et al., 2007). Studies in mice have shown that microglia can differentiate to functional antigen-presenting cells (APCs) (Ebner et al., 2013; Gottfried-Blackmore et al., 2009; Monsonego and Weiner, 2003; Wlodarczyk et al., 2015), and two recent single-cell RNA sequencing studies have shown subsets of microglia that appear in the course of neurodegeneration and potentially function as APCs (Keren-Shaul et al., 2017; Mathys et al., 2017). Although MHCII-expressing microglia emerge during neurodegeneration, their functional role as T-cell-stimulating APCs over the course of AD is as yet unclear.

Here, to determine the role of brain APCs in promoting the effector functions of T cells within the brain parenchyma, we ICV-injected Aβ-specific T cells to 5XFAD mice that lack MHCII-expressing cells, either entirely or only in the brain.

RESULTS

ICV Injection of Aβ-specific Th1 Cells to 5XFAD Mice Decreases Aβ Plaques, Which Is Associated with Increased Expression of MHCII by Parenchymal APCs

Using the APP/PS1 mouse model of AD, we have previously demonstrated that whereas T cell activation, but not antigen specificity, was required for ICV-injected T cells to migrate into the brain parenchyma, the induction of MHCII+ cells was more pronounced with Aβ- than with OVA-specific T cells (Fisher et al., 2014). We thus first examined whether ICV-injected Aβ-specific T helper 1 (Aβ-Th1) cells induce the expression of MHCII in the brain of the 5XFAD mouse model of AD. To this end, we generated GFP-expressing Aβ-Th1 cells by immunizing 2-month-old C57BL6 wild-type (WT) mice with Aβ1–42, followed by in vitro expansion, polarization, and a GFP-encoding retrovirus transduction of Aβ-Th1 cells (Figure S1 and Transparent Methods). Next, the GFP+ Aβ-Th1 cells underwent anti-CD3/anti-CD28 dynabeads activation and was ICV-injected (Figure 1A) to 9-month-old WT female mice (Th1/WT) or to 5XFAD female mice (Th1/AD), which accumulate amyloid plaques in the brain by age 2 months (Oakley et al., 2006). As control groups, age- and sex-matched WT and 5XFAD mice were ICV-injected with PBS (PBS/AD). Mice were killed at 11 or 21 days post-injection (dpi) and their brains were excised and analyzed with immunohistochemistry (IHC) and real-time quantitative PCR (qPCR). We found that the ICV-injected GFP+ T cells migrated into the brain parenchyma and that a portion of the cells accumulated at the vicinity of Aβ plaques (11 dpi, Figure 1B). Similar to our results in a previous study (Fisher et al., 2014), the amyloid burden in the brain of 9-month-old 5XFAD mice killed at 21 dpi was significantly reduced in the cortex of Th1/AD mice, when compared with PBS/AD mice (Figure 1C).

Next, we determined whether the enhanced clearance of Aβ in Th1/AD mice is associated with increased numbers of MHCII+ cells in the brain parenchyma. Notably, IHC analysis showed a significant increase in MHCII+ cells in close proximity to Aβ plaques, in the cortex (Figure 1D) of Th1/AD mice, but not in PBS/AD mice, and an upregulation of the invariant chain CD74 mRNA, which was analyzed using qPCR (Figure 1E). Brain sections immunolabeled with anti-MHCII and with either the cytoskeletal marker phalloidin, which labels F-actin (Figure 1F, upper panels), or anti-phospho-Zap70 (Zeta-chain-associated protein kinase 70), a protein kinase required for T cell activation (Figure 1F, lower panels), demonstrate the polarization of GFP+ T cells toward MHCII+ cells in the cortex and their activation, as indicated by Zap70 phosphorylation.

Taken together, these results demonstrate that the ICV-injected T cells upregulate MHCII by certain microglial subsets or infiltrating macrophages, which, in turn, appear to generate an immunological synapse with the injected T cells.

MHCII+ Cells Are More Phagocytic and less Ramified Than MHCII− Cells in 5XFAD Mice ICV-Injected with Aβ-Th1 Cells

Microglial accumulation around amyloid plaques is one of the classical hallmarks of AD. We and others have shown that, once recruited to plaques, microglia undergo morphological changes, such as increased...
Figure 1. ICV Injection of Aβ-Th1 Cells to 5XFAD Mice Decreases Aβ Plaques in the Brain Associated with Increased Expression of MHCII by Parenchymal APCs

Aβ-Th1 T cells were generated following the Aβ1–42 immunization of 2-month-old mice (Transparent Methods and Figure S1A). 5XFAD mice were ICV-injected with either Aβ-Th1 T cells or PBS, killed at 11 or 21 days post-injection (dpi), and their brains collected and analyzed by IHC or qPCR.

(A) Illustration of a representative coronal view of the adult mouse brain and the injection site in the lateral ventricle.

(B) A representative IHC image (left) of Aβ plaques co-localized with GFP+ T cells (green) in brain sections derived from 5XFAD mice 11 dpi of activated Aβ-Th1 cells. Sections were immunolabeled with anti-Aβ (red) and a DAPI nucleus counterstain (blue). The middle image is a higher magnification of the framed area, showing the interaction between Aβ and Aβ-Th1 T cells. The right image is a 3D reconstruction of z-sections (9.75 μm overall, 0.75 μm/slice) of the framed area. Scale bars, 200 μm (left), 50 μm (middle), and 5 μm (right).

(C) Representative IHC images showing Aβ plaque load in brain sections derived from 5XFAD mice ICV-injected with either PBS (PBS→AD, left) or Aβ-Th1 T cells (Th1→AD, right). Sections were taken at 21 dpi (n = 4–5 mice per group) and immunolabeled with anti-Aβ plaques (red) and a DAPI nucleus counterstain (blue). Scale bars, 200 μm. The quantitative analysis of the Aβ plaque load in the cortex (right graph) was performed with IMARIS and shows the mean ± SEM results of one experiment out of four performed.

(D) Representative IHC images showing the upregulation of MHCII+ cells in brain sections derived from either PBS→AD (left) or Aβ-Th1 T cells (Th1→AD, right) mice at 21 dpi (n = 6 mice per group), immunolabeled with anti-MHCII (green), anti-Aβ (red), and a DAPI nucleus counterstain (blue). The higher magnifications of the framed areas reveal MHCII+ cells accumulating near the Aβ plaques. Scale bars, 200 μm in the low-magnification images and 50 μm in the high-magnification images. The quantitative analysis of the number of MHCII+ cells per volume of cortical section (right graph) was performed with IMARIS. Each symbol represents an individual mouse, whereas the horizontal lines indicate the mean ± SEM of one experiment out of four performed.

(E) qPCR analysis of CD74 expression in the cortex (left) and hippocampus (right) of Th1→AD and PBS→AD mice at 21 dpi (n = 6–7 mice per group). Bars represent means ± SEM.

(F) Representative IHC images demonstrating an immunological synapse between MHCII+ cells and GFP+ T cells in brain sections derived from Th1→AD mice at 11 dpi (n = 5 mice) and immunolabeled with anti-phalloidin (cytoskeletal marker, blue), anti-MHCII (red), and GFP T cells (top images), or with anti-Zap70 (phospho Tyr 319) (red), anti-MHCII (blue), GFP T cells, and a DAPI nucleus counterstain (gray) (bottom images). In the top images, the middle and right panels are 3D reconstructions of z-sections (11.25 μm overall, 0.75 μm/slice). Scale bars, 10 μm. In the bottom images, the middle and right images are a 3D reconstruction of z-sections (7 μm overall, 0.5 μm/slice), which was then sliced in the xy axis. The front orientation of the xy-sliced 3D reconstruction shows an immunological synapse via Zap70 (phospho Tyr 319) (right). Scale bars, 10 μm (left) and 5 μm (middle and right images). *p < 0.05, **p < 0.01, ***p < 0.001 (C and D) Student’s t test and (E) one-way ANOVA.
soma size and thickened processes, which represent their activation state or their dysfunctional properties (Andreasson et al., 2016; Davies et al., 2017; Spittau, 2017; Walker and Lue, 2015). To test whether the MHCII+ cells are morphologically distinct from MHCII−/C0 cells and impact the phagocytic capacity of Aβ in the brain, we prepared sagittal brain sections from Th1/AD mice. The sections were immunolabeled for Iba1, MHCII, and Aβ, and the proportion of Aβ localized to MHCII+ cells was analyzed with the IMARIS software. A co-labeling IHC analysis revealed that MHCII+ cells primarily colocalize with Iba1+ and Aβ at the vicinity of plaque (Figure 2A). To determine whether the MHCII+ cells phagocytose Aβ, the reconstructed images were sliced in the xy plane using a clipping tool in IMARIS. The unsliced panels (Figure 2B; left, upper, and lower panels) show the interactions of MHCII+ and MHCII−/C0 cells with Aβ, whereas the xy-sliced panels (Figure 2B; right, upper, and lower panels) demonstrate Aβ engulfed by the cells. A quantitative analysis demonstrated that the MHCII+ cells co-localized with Aβ more efficiently than with MHCII−/C0 cells (Figure 2B), thus presumably indicating an upregulation of phagocytic activity.

To morphologically characterize MHCII+ and MHCII−/C0 cells, confocal z stacks were captured and the images were manually traced by the backbone of the cells, using the IMARIS Filament Tracer plug-in. The tree area, total branch length, and number of bifurcations were calculated with IMARIS. We found that, whereas MHCII−/C0 microglia show the typical ramified morphology, the MHCII+ cells that surround the plaques exhibit a more amoeboid-like morphology with an enlarged soma size (Figure 2C). A manual 3D reconstruction of MHCII− and MHCII+ cells is shown in Figure 2C. Quantitative analyses of the
reconstructed images show that MHCII+ Iba1+ cells exhibit a decrease in the spatial coverage area (Figure 2D), process length (Figure 2E), and process bifurcation (Figure 2F), when compared with MHCII− Iba1+ cells. This finding suggests that the MHCII+ Iba1+ subset of cells, which expands in 5XFAD mice upon an ICV injection of Aβ-specific Th1 cells, may represent a beneficial response in the brain by reducing plaque burden.

**MHCII-Knockout 5XFAD Mice Exhibit an Exacerbated Amyloid Pathology**

MHCII expression by myeloid cells is essential for the selection and activation of CD4 T cells, a process that may facilitate the overall uptake of Aβ in the brain. Therefore, we backcrossed 5XFAD mice onto MHCII-knockout (KO) background mice to generate 5XFAD mice that lack MHCII (5XFAD/MHCII−/− mice). Age-matched littermates were used as WT and 5XFAD control groups (Figures 3A and S2). Then we characterized the inflammatory reaction in the brain and the accumulation of Aβ plaques in 5XFAD/MHCII−/− and 5XFAD mice at 1, 3, and 6 months age. Brain sections were first immunolabeled with anti-Aβ, and the volume occupied by Aβ plaques in the cortex was calculated using IMARIS. Surprisingly, and despite the use of an aggressive model of amyloidosis, we found that Aβ accumulated in the brain by 1 month age in 5XFAD/MHCII−/−, whereas almost no plaques were observed in 5XFAD mice (Figure 3B). Furthermore, at older ages, the volume of Aβ plaques in 5XFAD/MHCII−/− mice was nearly 2-fold higher than in 5XFAD mice (Figure 3B). To determine whether gene expression indicating inflammatory reaction in the brain was similarly upregulated in 5XFAD and 5XFAD/MHCII−/− mice, we used qPCR. A significant upregulation of mRNAs encoding interleukin (IL)-1β and glial fibrillary acidic protein (GFAP) was found in 5XFAD and in 5XFAD/MHCII−/− mice, when compared with littermate control mice, both at 3 and 6 months of age (Figure 3C). The mRNA levels of IL-6 and interferon (IFN)-γ were not upregulated in either 5XFAD or 5XFAD/MHCII−/− mice at 3 months of age, whereas they were significantly upregulated in 5XFAD/MHCII−/− mice at 6 months of age, when compared with either 5XFAD or littermate control mice (Figure 3C).

To determine whether the increase in plaque pathology observed in 5XFAD/MHCII−/− mice was due to a reduced clearance of Aβ in the brain, we used high-resolution confocal microscopy and 3D image reconstruction. Brain sections from 6-month-old 5XFAD/MHCII−/− and 5XFAD mice were immunolabeled for Aβ and Iba1 and the proportion of Aβ engulfed by activated microglia was analyzed. Notably, the 3D reconstruction of the IHC image showed that whereas Iba1+ cells penetrated the plaques in 5XFAD mice, they were primarily in the plaque vicinity in 5XFAD/MHCII−/− mice (Figure 3D). Furthermore, the 3D reconstructed image was sliced in the xy axis using IMARIS, demonstrating Aβ engulfed by the Iba1+ cells. A quantitative analysis of the fraction of Aβ co-localized with microglia was significantly lower in brain sections of 5XFAD/MHCII−/− (0.26% ± 0.06%) than in those of 5XFAD mice (0.54% ± 0.06%) (Figure 3D).

Immunolabeling for Aβ, Iba1, and the lysosome marker CD68 revealed a marked decrease in Iba1+ CD68+ cells co-localized with Aβ plaques in the brain of 5XFAD/MHCII−/− mice (Figure S3). In addition, the qPCR analysis demonstrated a decrease in the mRNA levels of the phagocytic markers TREM-2 and SIRP-1β in the brain of 5XFAD/MHCII−/−, when compared with those in the brain of 5XFAD mice, which was significant for both genes at 6 months of age, and only for SIRP-1β at 3 months of age (Figure 3E). Taken together, these results indicate that, in the absence of MHCII, the phagocytic capacity of microglia in the brain is reduced; this is accompanied by a dysregulation of the inflammatory reaction in the brain and an exacerbated Aβ pathology.

**ICV-Injected Aβ-Th1 Cells Exhibit Reduced Effector Functions in 5XFAD/MHCII−/− Mice**

To determine whether the exacerbated pathology observed in 5XFAD/MHCII−/− mice can be recovered by using activated CD4 T cells, we subjected Aβ-Th1 cells to polyclonal activation with anti-CD3/anti-CD28 dynabeads and ICV-injected them to 7-month-old 5XFAD/MHCII−/− mice and to 5XFAD mice. Mice were killed at 21 dpi, a time required to determine T cell effector functions induced by brain APCs, and their brains were analyzed for the presence of CD4 T cells, Aβ plaque load, and inflammatory mediators. Surprisingly, IHC analysis of the cortex revealed that although the CD4 T cells migrated into the brain of 5XFAD/MHCII−/−, no differences in plaque load were observed, when compared with mice ICV-injected with PBS (Figures 4A and 4B). Furthermore, the qPCR analysis showed that the mRNAs encoding the Th1 cytokine IFN-γ and the chemokines CXCL9, CXCL10, and CXCL11, which are ligands of the CXCR3 receptor on Th1 T cells, were only slightly upregulated in 5XFAD/MHCII−/− mice ICV-injected with Th1 cells, when compared with 5XFAD mice ICV-injected with Th1 cells (Figure 4C). In light of these observations, we sought to determine whether the reduced clearance of Aβ in 5XFAD/MHCII−/− mice ICV-injected with
Aβ-Th1 cells is due to a reduced monocyte infiltration into the brain. To test this hypothesis, brain cells were isolated enzymatically from all the groups of mice at 21 dpi and analyzed with flow cytometry. Single cells were gated for CD45+ CD11b+ myeloid cells, which were then analyzed for putative infiltrating CX3CR1/Ly6C+ macrophages (Figure 4D). CX3CR1/Ly6C+ cells were indeed observed in the brain of 5XFAD mice that had been ICV-injected with Aβ-Th1 cells; however, this phenomenon was observed neither in 5XFAD/MHCII−/− mice ICV-injected with Aβ-Th1 cells nor in the respective PBS-injected control groups (Figures 4E and S4).

Taken together, these results indicate that MHCII expression by microglia or infiltrating macrophages results in the stimulation of T cells, which consequently impacts the inflammatory milieu and Aβ accumulation.
Microglial Expression of MHCII Is Required to Stimulate the Effector Functions of ICV-Injected Aβ-Th1 Cells within the Brain Parenchyma

The ICV injection of Aβ-Th1 cells to 5XFAD/MHCII−/− mice did not result in T cell activation within the brain and, therefore, the T cells did not significantly impact the immune milieu or reduce the plaque load in the brain (Figure 4). However, these findings do not indicate whether the re-stimulation of the ICV-injected Aβ-Th1 cells in the brain of 5XFAD mice is mediated by peripheral APCs or, alternatively, by APCs within the brain parenchyma. To answer this question, we generated WT GFP/GFP 5XFAD/MHCII−/− bone marrow (BM) chimera (BMC) mice in which MHCII+ BM is transplanted to 5XFAD/MHCII−/− (Transparent...
Methods). Of the 12 mice that received BM transplants, six were injected with Aβ-Th1 cells 8 weeks after the BM transplantation. Then, at 28 dpi, the mice were perfused and their brains were excised and analyzed by IHC and flow cytometry. As expected, the IHC analysis revealed enhanced infiltration of GFP+ BM-derived cells in BMC mice that were ICV-injected with Aβ-Th1 cells, when compared with untreated BM-transplanted mice (Figure 5A); however, the accumulation of the infiltrating GFP+ BM-derived cells around Aβ plaques remained similar in both groups (Figure 5B). Next, we determined the Aβ pathology of BMC mice that were either ICV-injected or not injected with Aβ-Th1 cells and compared it with untreated 5XFAD/MHCII−/− mice. An IHC analysis of the amyloid burden in the cortex of BMC mice revealed that, when compared with untreated 5XFAD/MHCII−/− mice, the plaque volume was significantly reduced (Figure 5C). Regardless of the enhanced infiltration of GFP+ BM-derived cells into the brains of 5XFAD/MHCII−/− mice ICV-injected with Aβ-Th1 cells (Figure 5A), no further reduction in Aβ was observed in these mice, when compared with the non-injected BMC mice (Figure 5C). Notably, the GFP+ macrophages infiltrating into the brain parenchyma were mostly detected as MHCII+ cells in BMC mice that were either ICV-injected or not injected with T cells (Figure 5D).

The results shown in Figure 5 suggest that the MHCII+ cells observed in 5XFAD mice ICV-injected with Aβ-Th1 cells are primarily brain-endogenous microglia. To determine that microglia can indeed give rise to MHCII+ cells, 8- or 9-month-old 5XFAD mice were ICV-injected with Aβ-Th1 cells and their brains
were subjected to flow cytometry analysis at 21 dpi. Single cells were first gated for the CD45+ CD11b+ cells, and the gated cells were then plotted with the MHCII and Ly6C myeloid markers (Figures 6A–C). The fraction of MHCII+ cells out of the CD45+ CD11b+ cells was then analyzed for all groups (PBS→ littermates, PBS→ 5XFAD, and Th1→ 5XFAD), revealing a significant increase in MHCII+ cells in the brain

Figure 6. Aβ-Th1 T Cells Upregulate MHCII Expression in Brain Endogenous Microglia of 5XFAD Mice

SXFAD and littermate (litt.) control mice were ICV-injected with either Aβ-Th1 T cells or PBS, killed at 14 or 21 dpi, and their brains excised and analyzed by using RNAscope (14 dpi) or flow cytometry (21 dpi).

(A) Flow cytometry plots demonstrating the gating strategy from single cells (left) to myeloid cells (CD45+ CD11b+; right).

(B) Flow cytometry plots demonstrating MHCII+ cells (out of CD11b+ CD45+ cells) in PBS→ litt mice (left), PBS→ 5XFAD mouse (middle), and Th1→ 5XFAD mice (right). The frequency of MHCII+ cells was quantified for all groups (right graph). Each symbol represents an individual mouse (n = 5 mice per group), and the bars represent means ± SEM of one experiment out of four performed.

(C) Flow cytometry plots demonstrating Ly6C+ cells (out of MHCII+ CD11b+ CD45+ cells) in the above-mentioned groups. The frequency of Ly6C+ cells was quantified for all groups (right graph). Each symbol represents an individual mouse (n = 5 per group), and the bars represent means ± SEM.

(D) Representative RNAscope fluorescence in situ hybridization images showing the co-expression of CD74 (red), P2ry12 (green) mRNA, and a DAPI nucleus counterstain (blue) in brain sections derived from Aβ-Th1→ 5XFAD mice (n = 5).

(E) A representative image showing P2ry12 (green) and CD74- (red) expressing cells. A higher magnification merge image of the framed area (top right panel) and the single-channel images (lower panels) show P2ry12+ (white arrows), P2ry12– (pink arrows), and CD74+ (yellow arrows) cells. Scale bars, 50 and 10 μm. *p < 0.05, ***p < 0.001 (one-way ANOVA).
parenchyma of mice ICV-injected with Aβ-Th1 cells (9.79% ± 1.29%), when compared with mice ICV-injected with PBS (3.95% ± 0.39%; Figure 6B). MHCII+ cells from each group were then plotted for the Ly6C marker, which revealed 28.16% ± 0.77% and 63.56% ± 5.13% cells within the presumed infiltrating CD45+ CD11b+ Ly6C<sup>hi</sup> macrophages and brain-endogenous CD45+ CD11b+ Ly6C<sup>lo</sup> microglia, respectively (Figure 6C). Next, we conducted an RNAscope fluorescence in situ hybridization at 14 dpi to identify the MHCII+ cells in the brains of SxFAD mice ICV-injected with Aβ-Th1 cells. P2ry12 and CD74 were used as markers of endogenous microglia (Butovsky et al., 2014; Zhu et al., 2017) and MHCII+ cells, respectively. Ppib (peptidyl-prolyl cis-trans isomerase B) was used as a positive control (Figure 6D). These analyses revealed that CD74 mRNA (yellow arrows) is expressed primarily in microglia cells expressing the P2ry12 mRNA (white arrows) (Figure 6E). Note that not all P2ry12-expressing microglia express CD74 and that, as expected, some cells are negative to both markers (pink arrow). Overall, these data suggest that the MHCII+ cells, which were observed in SxFAD mice and with increased frequencies in SxFAD mice ICV-injected with Aβ-Th1 cells, are primarily endogenous microglia.

**DISCUSSION**

The aim of the current study was to test whether T cells can promote the differentiation of myeloid cells in the brain parenchyma into APCs with enhanced Aβ uptake capacity. We demonstrate that Aβ-Th1 cells, ICV-injected to SxFAD mice, not only migrate into the brain parenchyma but also stimulate the expansion of MHCII+ cells. This process is associated with the activation of T cells, the modulation of the inflammatory reaction to Aβ pathology, and enhancement of Aβ uptake. We found that the newly differentiated MHCII+ cells originate primarily from brain-endogenous microglia. As such, this subset of MHCII+ microglia may serve to target therapeutic antigen-specific T cells directly to damaged sites within the CNS.

We have previously shown that Aβ-specific T cells polarized to Th1 T cells and ICV-injected to APP/PS1 mice transmigrate into the brain parenchyma, where they impact the inflammatory response induced by Aβ and enhance amyloid plaque uptake (Fisher et al., 2014). However, it was unclear whether these T cells undergo reactivation by APCs within the brain parenchyma in a manner that stimulates their effector functions. Here, we found that MHCII+ cells expand in the brain parenchyma following an ICV injection of Aβ-Th1 cells. Moreover, we show that these MHCII+ cells accumulate in the vicinity of Aβ plaques and exhibit a less ramified morphology and enhanced phagocytic capacity, when compared with Iba+ microglia. Finally, we found that the MHCII+ cells interact with the injected T cells in a manner reminiscent of an immunological synapse, which is essential for T cell activation. Taken together, our findings suggest that, within the brain parenchyma, brain-infiltrating Aβ-Th1 cells can stimulate the differentiation and expansion of MHCII+ cells, whose phagocytic and antigen presentation capacity is considerably greater than those of MHCII− microglia.

Although MHCII in activated microglia is known to be upregulated at the vicinity of plaques in brains of people with AD (Hopperton et al., 2018; Parachikova et al., 2007; Schetters et al., 2017; Tooyama et al., 1990) and in mouse models of the disease (Landel et al., 2014; Mathys et al., 2017), it remains unclear whether MHCII expression by microglia or infiltrating macrophages plays a role in the progression of AD. Surprisingly, we found that SxFAD/MHCII<sup>-/-</sup> mice, which lack MHCII, exhibit a worsened amyloid pathology compared with SxFAD mice, and that this pathology is accompanied by an enhanced innate inflammation. Furthermore, the Aβ phagocytic capacity of microglia in SxFAD/MHCII<sup>-/-</sup> mice was significantly reduced and the mRNA expression of SIRP-β1 and TREM2—two genes that play important roles in the activation and phagocytic machinery of microglia and macrophages in the brain (Finelli et al., 2015; Gaikwad et al., 2009; Hickman and El Khoury, 2014; Rivest, 2015; Zhang et al., 2015)—was downregulated. Notably, in contrast to SIRP-β1, TREM2 was significantly upregulated in SxFAD mice (Keren-Shaul et al., 2017; Wang et al., 2015, 2016) and was slightly downregulated in SxFAD/MHCII<sup>-/-</sup> mice. These results suggest that CD4 T cell effector functions are required to effectively stimulate the phagocytic capacity of microglia within the brain, a mechanism that may involve not only the upregulation of phagocytic molecules but also the downregulation of inhibitory receptors such as LILRB1 (Barkal et al., 2018). In line with these findings, a recent study demonstrated that Aβ uptake is reduced in a Rag-SxFAD mouse model of AD, which lacks the entire cellular and humoral adaptive arms of the immune system, and that IgG treatment enhances the uptake of Aβ in these mice (Marsh et al., 2016). Overall, it is suggested that both humoral and cellular immune responses—orchestrated by CD4 T cells—play a significant role in the capacity of the brain to clear Aβ.
Another important finding in this study was that, although we activated the Aβ-Th1 cells before their ICV injection, they exhibited significantly reduced effector functions (as indicated by the reduced mRNA levels of IFN-γ and CXCL9/10/11 chemokines and by the significantly reduced number of presumed infiltrating macrophages) in the brains of 5XFAD/MHCII−/− mice, when compared with 5XFAD mice. These findings suggest that the effector functions of the ICV-injected Aβ-Th1 cells are facilitated by antigen presentation in the brain. It, however, remained unclear whether this T cell re-stimulation is mediated by brain-endogenous microglia or by peripheral macrophages. Generating a WTGFP/GFP→ 5XFAD/MHCII−/− BMC mice, we recovered the leukocyte repertoire and turnover of the meningeal macrophages to MHCII+ cells, and thus, except for some infiltrating GFP+ cells, microglia in the brain of the BMC mice remained MHCII−. Notably, whereas recovering the peripheral and meningeal leukocytes in the BMC mice reduced the amyloid load in the brain, the ICV-injected cells did not facilitate this reduction. These results strongly suggest that brain-endogenous MHCII+ microglia are required to re-stimulate the T cells. In line with our findings, a subset of MHCII+ microglia was recently observed in a mouse model of neurodegeneration and was suggested to be a type-II IFN-induced subset of microglia, which may potentially function as APCs (Mathys et al., 2017). In addition, this subset is highly similar to disease-associated microglia, a subset that was recently reported in the 5XFAD mouse model of AD (Keren-Shaul et al., 2017). More recently, a subset of MHCII+ microglia was observed within activated response microglia (ARMs) in a mouse model of AD (Sala Frigerio et al., 2019). Interestingly, ARMs were more frequent in female than in male mice (Sala Frigerio et al., 2019), suggesting a gender variation in microglial phenotypes (Nelson et al., 2017; VanRyzin et al., 2019), which may affect their activation profile in aging and disease. Taking together, a relatively low frequency of MHCII+ microglia accumulate in the brain during inflammation, a phenomenon that calls for further research to explore their origin, molecular characteristics, differentiation program, and functional properties.

Overall, our study suggests that the function of microglia as APCs plays an important role in brain immunity, which, based on the T cell phenotype (Th1, Th2, Th17, or regulatory T cells [Tregs]), can exert either beneficial or neurotoxic responses. We have previously shown that the Th1 subset of cells is the most effective subset in preconditioning the brain for T cell migration, primarily due to IFN-γ being the key cytokine that these T cells secrete (Fisher et al., 2014). Hence, IFN-γ appears to be required to promote the differentiation of certain subsets of microglia to APCs, thereby acquire an enhanced phagocytic capacity (Fisher et al., 2014; Gottfried-Blackmore et al., 2009; Monsonego and Weiner, 2003), as well as to promote the various neuroprotective functions observed in animal models, such as in the induction of IL-6 expression in astrocytes during acute neuroinflammation (Sun et al., 2017), the induction of IL-10 after spinal cord injury (Ishii et al., 2013), and the induction of neurogenesis (Mastrangelo et al., 2009). The Th1 cells may be the only first arrivals into the brain, paving the way for regulatory T cells such as Th2/Tr1 or Foxp3+ Tregs, which were found to be important for immune regulation in mouse models of neurodegenerative diseases (Baruch et al., 2015; Kipnis et al., 2004; Mayo et al., 2016; Ochi et al., 2008; Perdigoto et al., 2015). It cannot be excluded, though, that leukocytes such as CD8 T cells (Lassmann, 2018; Lassmann and Bradl, 2017), natural killer cells, and neutrophils (Cruz Hernandez et al., 2019) may also infiltrate the brain and cause neurotoxicity. It is thus intriguing to examine whether the dysregulated CD4 T cells that are observed with aging (Harpaz et al., 2017; Moro-Garcia et al., 2013; Nikolich-Zugich, 2018) fail to properly regulate adaptive immunity in the brain and, therefore, facilitate neurotoxic inflammation and the progression of AD. This process of immune senescence may also explain why immunotherapies suitable for adults are not always effective for elderly individuals. Further characterizing immune senescence processes and their impact on neurotoxic inflammation may thus pave the way toward therapeutic approaches that target peripheral immune senescence, thus allowing a proper dialog between brain-infiltrating CD4 T cells and MHCII-expressing microglia, which may be required to promote neural repair in the AD brain.
Limitations of the Study

1. qPCR was used in the current study to analyze the expression of inflammatory genes in the brain. As some of these markers were not measured at the protein level, they represent transcriptional changes that do not necessarily define the proinflammatory phenotype of the cells.

2. Our experimental setup was based on ICV—rather than intravenous— injection of T cells, a process that may cause acute microglial activation and hence a relatively robust differentiation of microglial subsets to APCs.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.05.039.

ACKNOWLEDGMENTS

We thank Dr. Ram Gal for his valuable comments on the manuscript. This work was supported by the Israel Science Foundation (# 684/14) and the Litwin and Gural Foundations.

AUTHOR CONTRIBUTIONS

K.M. designed the study, performed and analyzed experiments, and drafted the manuscript. E.E., O.B., Y.E., D.A., I. Strominger, and I. Spiegel, performed and analyzed experiments. A.N. contributed technical expertise. A.M. designed and supervised the study and wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests. The corresponding author has a patent entitled “T-cell therapy to neurodegenerative diseases.”

Received: November 18, 2018
Revised: April 1, 2019
Accepted: May 28, 2019
Published: June 28, 2019

REFERENCES

Anderson, K.M., Olson, K.E., Estes, K.A., Flanagan, K., Gendelman, H.E., and Mosley, R.L. (2014). Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl. Neurodegener. 3, 25.

Andreasson, K.I., Bachstetter, A.D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D.C., Low, D., Lynch, M.A., et al. (2016). Targeting innate immunity for neurodegenerative disorders of the central nervous system. J. Neurochem. 138, 653–693.

Baek, H., Ye, M., Kang, G.H., Lee, C., Lee, G., Choi, D.B., Jung, J., Kim, H., Lee, S., Kim, J.S., et al. (2016). Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer’s disease model. Oncotarget 7, 69347–69357.

Barkal, A.A., Werskopf, K., Kao, K.S., Gordon, S.R., Rosental, B., Yiu, Y.Y., George, B.M., Markovic, M., Ring, N.G., Tsi, J.M., et al. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76–84.

Baruch, K., Deczkowska, A., Rosenzweig, N., Tsitsou-Kampeli, A., Sharif, A.M., Matcovitch-Natan, O., Kertser, A., David, E., Amit, I., and Schwartz, M. (2016). PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 22, 135–137.

Baruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A.M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., and Schwartz, M. (2015). Breaking immune tolerance by targeting Foxp3(−) regulatory T cells mitigates Alzheimer’s disease pathology. Nat. Commun. 6, 7967.

Black, M.L., Zecca, L., and Hong, J.S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69.

Bryson, K.J., and Lynch, M.A. (2016). Linking T cells to Alzheimer’s disease: from neurodegeneration to neurorepair. Curr. Opin. Pharmacol. 26, 67–73.

Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. (2014). Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143.

Chiu, I.M., Chen, A., Zheng, Y., Kosaras, B., Tsifstogiou, S.A., Vartanian, T.K., Brown, R.H., Jr., and Carroll, M.C. (2008). T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U S A 105, 17913–17918.

Cruz Hernandez, J.C., Bracko, O., Kersbergen, C.J., Muse, V., Haft-Javaherian, M., Berg, M., Park, L., Vinarsca, L.K., Ivasyk, I., Rivera, D.A., et al. (2019). Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat. Neurosci. 22, 413–420.

Dansokho, C., Ait Ahmed, D., Aid, S., Toly-Ndour, C., Chaingneau, T., Calle, V., Cagnard, N., Holzenberger, M., Piaggio, E., Aucouturier, P., et al. (2016). Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139, 1237–1251.
Davies, D.S., Ma, J., Jegathees, T., and Goldsby, C. (2017). Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer’s disease. Brain Pathol. 27, 795–806.

Ebner, F., Brandt, C., Thiele, P., Richter, D., Schliesser, U., Siffirn, V., Schueler, J., Stubbie, T., Ellinghaus, A., Messele, et al. (2013). Microglial activation milieu controls regulatory T cell responses. J. Immunol. 191, 5594–5602.

Finelli, D., Rollinson, S., Harris, J., Jones, M., Richardson, A., Gerhard, A., Snowden, J., Mann, D., and Pickering-Brown, S. (2015). TREM2 analysis and increased risk of Alzheimer’s disease. Neurobiology. Aging 36, 6459–6413.

Fisher, Y., Strominger, J., Biton, S., Nemirovsky, A., Baron, R., and Monsonego, A. (2014). Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. J. Immunol. 192, 92–102.

Gaikwad, S., Larionov, S., Wang, Y., Dannenberg, H., Matsuzaki, T., Monsonego, A., Thal, D.R., and Neumann, H. (2009). Signal regulatory protein-beta1: a microglial modulator of phagocytosis in Alzheimer’s disease. Am. J. Pathol. 175, 2528–2539.

Giannakopoulos, P., Herrmann, F.R., Bussiere, T., Bouras, C., Kovari, E., Perl, D.P., Morrison, J.H., Giannakopoulos, P., Herrmann, F.R., Bussiere, T., et al. (2009). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60, 1495–1500.

Gottfried-Blackmore, A., Kaufner, U.W., Idoyaga, J., Felger, J.C., McEwen, B.S., and Bulloch, K. (2009). Acute in vivo exposure to Idoidaga, J., Felger, J.C., McEwen, B.S., and Hof, P.R. (2003). Tangle and neuron status in Alzheimer’s disease. Neurology 60, 1929–1931.

Harpaz, I., Bhattacharya, U., Elyahu, Y., Strominger, I., and Monsonego, A. (2017). Old mice accumulate activated effector CD4 T cells refractory to regulatory T cell-induced immunosuppression. Front. Immunol. 8, 283.

Heneka, M.T., Carson, M.J., Khoury, J.E., Landreth, G.E., Brosseron, F., Feinstein, D.L., Heneka, M.T., Carson, M.J., Khoury, J.E., et al. (2012). Temporal gene profiling of the SFXD1 transgenic mouse model highlights the importance of microglial activation in Alzheimer’s disease. Mol. Neurodegener. 9, 33.

Hopperton, K.E., Mohammad, D., Trepanier, M.O., Giuliano, V., and Bazinet, R.P. (2018). Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol. Psychiatry 23, 177–198.

Hoppman, N., Graetz, C., Paterka, M., Poisa-Beiro, L., Larochelle, C., Hasan, M., Lill, C.M., Zipp, F., and Siffrin, V. (2015). New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain 138, 902–917.

Iqbal, K., Liu, F., and Gong, C.X. (2016). Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurosci. 12, 15–27.

Ishii, H., Tanabe, S., Ueno, M., Kubo, T., Kayama, H., Serada, S., Fujimoto, M., Takeda, K., Naka, T., and Yamashita, T. (2013). IFN-gamma-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injury. Cell Death Dis. 4, e710.

Kamphuis, W., Kooijman, L., Schutters, S., Orre, M., and Hol, E.EM. (2016). Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer’s disease. Biochim. Biophys. Acta. 1862, 1847–1860.

Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Divir-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astasio, D., Toth, B., et al. (2017). A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e17.

Kipnis, J., Avidan, H., Caspi, R.R., and Schwartz, M. (2004). Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl. Acad. Sci. U S A 101 (Suppl 2), 14663–14669.

Landel, V., Baranger, K., Virard, I., Loriod, B., Krestchatisky, M., Rivera, S., Benech, P., and Feron, F. (2014). Temporal gene profiling of the SFXD1 transgenic mouse model highlights the importance of microglial activation in Alzheimer’s disease. Mol. Neurodegener. 9, 33.

Lassmann, H. (2018). Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front. Immunol. 9, 3116.

Lassmann, H., and Bradl, M. (2017). Multiple sclerosis: experimental models and reality. Acta Neuropathol. 133, 223–244.

Liesz, A., Suri-Payer, E., Veltkamp, C., Doerr, H., Sommer, C., Rivest, S., Giese, T., and Veltkamp, R. (2009). Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 15, 192–199.

Marsh, S.E., Abud, E.M., Lakatos, A., Karimzadeh, A., Yeung, S.T., Davryan, H., Fote, G.M., Lau, L., Weinger, J.G., Lane, E., et al. (2016). The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. U S A 113, E1316–E1325.

Mastrangelo, M.A., Suddi, K.L., Narrow, W.C., and Bowers, W.J. (2009). Interferon-gamma differentially affects Alzheimer’s disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 175, 2066–2088.

Mathys, A., Adakkan, C., Gao, F., Young, J.Z., Manet, E., Hemburg, M., De Jager, P.L., Ransohoff, R.M., et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405.

Hickman, S.E., and El Khoury, J. (2014). TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem. Pharmacol. 88, 495–498.

Hopperton, K.E., Mohammad, D., Trepanier, M.O., Giuliano, V., and Bazinet, R.P. (2018). Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol. Psychiatry 23, 177–198.

Hoppman, N., Graetz, C., Paterka, M., Poisa-Beiro, L., Larochelle, C., Hasan, M., Lill, C.M., Zipp, F., and Siffrin, V. (2015). New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain 138, 902–917.

Iqbal, K., Liu, F., and Gong, C.X. (2016). Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurosci. 12, 15–27.
Re, F., Belyanskaya, S.L., Riese, R.J., Capriani, B., Fischer, F.R., Granucci, F., Ricciardi-Castagnoli, P., Brosnan, C., Stern, L.J., Strominger, J.L., et al. (2002). Granulocyte-macrophage colony-stimulating factor induces an expression program in Neonatal Microglia that primes them for antigen presentation. J. Immunol. 169, 2264–2273.

Rivest, S. (2015). TREM2 enables amyloid beta clearance by microglia. Cell Res. 25, 535–536.

Russo, M.V., and McGavern, D.B. (2015). Immune surveillance of the CNS following infection and injury. Trends Immunol. 36, 637–650.

Sala Frigerio, C., Wolfs, L., Fattorelli, N., Trupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.T., Woodbury, M.E., Srivastava, G., et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160, 1061–1071.

Wang, Y., Ulland, T.K., Ulrich, J.D., Song, W., Tzaferis, J.A., Hole, J.T., Yuan, P., Mahan, T.E., Shi, Y., Gillfillan, S., et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667–675.

Wlodarczyk, A., Cedile, O., Jensen, K.N., Jasson, A., Mony, J.T., Khoroooshi, R., and Owens, T. (2015). Pathologic and protective roles for microglial subsets and bone marrow-derived myeloid cells in central nervous system inflammation. Front. Immunol. 6, 463.

Wyss-Coray, T., and Rogers, J. (2012). Inflammation in Alzheimer disease: a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346.

Zhang, H., Li, F., Yang, Y., Chen, J., and Hu, X. (2015). SRP/CpA7 signaling in neurological disorders. Brain Res. 1623, 74–80.

Zhu, C., Kros, J.M., van der Weiden, M., Zheng, P., Cheng, C., and Mustafa, D.A. (2017). Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. Acta Neuropathol. Commun. 5, 4.

Zota, V., Nemirovsky, A., Baron, R., Fisher, Y., Selkoe, D.J., Altmann, D.M., Weiner, H.L., and Monsonego, A. (2009). HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J. Immunol. 183, 3522–3530.

Zotova, E., Nicolli, J.A., Kalaria, R., Holmes, C., and Boche, D. (2010). Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res. Ther. 2, 1.
Supplemental Information

CD4 T Cells Induce A Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology

Kritika Mittal, Ekaterina Eremenko, Omer Berner, Yehezqel Elyahu, Itai Strominger, Daniella Apelblat, Anna Nemirovsky, Ivo Spiegel, and Alon Monsonego
Figure S1, related to Figure 1. Generation of GFP+ Aβ-specific Th1 T cells.

(A) A scheme demonstrating the generation of GFP+ Aβ-specific Th1 T cells (Aβ-Th1 cells) as detailed in Transparent Methods. (B) Cytokine secretion was measured following to bead (upper panels) or Aβ (lower panels) stimulation of Aβ-Th1 cells was analyzed by sandwich ELISA. IL-2 and IL-4 were measured 24 h after stimulation and IFN-γ and IL-10 were measured 48 h after stimulation. Bar graphs represent means ± SEM. (C-F) FACS analysis of activated GFP+ Aβ-Th1 cells performed 36 h after activation demonstrating that the majority of lympho-gated cells (C) are GFP+ (D), CD4+ (E), and CD25+ (F).
Figure S2, related to Figure 3. 5XFAD/MHCII<sup>−/−</sup> mice lack peripheral MHCII+ and CD4+ T cells.

Immune-deficient 5XFAD mice lacking MHCII (5XFAD/MHCII<sup>−/−</sup>) were generated and analyzed with FACS (n = 4 mice per group) for CD4, CD8 and MHCII positive cells in the spleen at 6 months of age. (A-C) t-distributed stochastic neighbor embedding (t-SNE) plots demonstrating the distribution of CD4 (A), CD8 T cells (B) and MHCII (C) cells among splenocytes derived from 5XFAD (left panels) and 5XFAD/MHCII<sup>−/−</sup> mice (right panels). The areas framed in red rings represent the frequency of the CD4+, CD8+, and MHCII+ cell subsets in the spleen. The color bar represents the mean fluorescence intensity (MFI) ranges from blue (lowest) to red (highest) color. (D-F) Histogram FACS plots showing the lack of CD4+ (D) and MHCII+ (F) cells in the spleen of 5XFAD/MHCII<sup>−/−</sup> mice as compared with 5XFAD mice, while the CD8 subset (E) remains intact.
Figure S3, related to Figure 3. Microglial phagocytosis is impaired in 5XFAD/MHCII−/− mice.

5XFAD/MHCII−/− and age-matched 5XFAD mice (n = 4–5 mice per group) were killed at 6 months of age, and their brains were analyzed by IHC. Brain sections were immunolabeled for Aβ (red), Iba1 (green), and CD68 (blue). (A and F) Representative IHC images showing Aβ co-localized with Iba1 and CD68. (B–D and G–I) 3D reconstruction of single channel images showing Iba1+ activated microglia (B, G) and microglial phagolysosome with CD68 (C, H) and Aβ plaques (D, I). (E, J) Colocalization of Aβ and CD68. (K) Quantification of Aβ internalization ratio (Aβ within phagolysosomes, normalized to total Aβ within the field) revealed a significant decrease in Aβ internalization in 5XFAD/MHCII−/− (0.2579 ± 0.02613; n=3) microglia compared with 5XFAD mice (0.6020 ± 0.02819; n=3). Bars represent means ± SEM. ***p < 0.001 (Student’s t-test).
Figure S4, related to Figure 4. CX3CR1–Ly6C+ macrophages are not increased in brains of 5XFAD/MHCII−/− mice ICV-injected with Aβ-Th1 T cells.

5XFAD and 5XFAD/MHCII−/− mice were ICV-injected with either Aβ-Th1 T cells or PBS (n = 4–5 mice per group). The mice were killed at 21 dpi and their brains were excised and analyzed with flow cytometry as described in Transparent Methods. (A) Flow cytometry plots demonstrating the frequency of CD11b+CD45low and CD11b+CD45high cells. (B) The frequency of CX3CR1–Ly6C+ macrophages. The results represent one experiment out of two performed.
Transparent Methods

Animals

Wild-type (WT) C57BL/6 mice (stock number 000664), 5XFAD transgenic (Tg) mice (Swedish K670N, M671L, Florida I716V, London V717I, and two mutations in the human presenilin-1 gene M146L and L286V; stock number 34848) (Oakley et al., 2006), UBC-GFP mice (stock number 004353), and MHCII knockout (KO) mice (stock number 003584) (Madsen et al., 1999) were purchased from the Jackson Laboratory (Bar Harbor, ME). 5XFAD and MHCII KO mice were backcrossed to C57BL/6J mice for more than 10 generations. 5XFAD mice lacking MHCII (5XFAD/MHCII–/–) were generated by backcrossing 5XFAD Tg mice onto an MHCII KO background. Female mice were used throughout the study. All surgical methods, materials, and immunization procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Ben-Gurion University of the Negev (Beer Sheva, Israel; approval number IL-70-10-2012).

Immunohistochemistry

Mice were killed with an overdose of isoflurane and perfused with cold PBS. Their brains were removed, immersed overnight in a 4% paraformaldehyde solution at 4 °C, transferred for 48 h to a freshly prepared 30% sucrose solution at 4 °C, and fixed in OCT (Tissue-Tek, Torrance, CA). Sagittal sections (35 mm) of the brains were produced with a cryostat (Leica CM3050, Rhenium Diagnostic, Israel) and kept at –20 °C until used. Sections were rinsed twice in a washing solution (0.05% PBS/Tween 20)
and permeabilized for 30 min in a 0.5% PBS/Triton X-100 solution. Prior to staining, a primary antibody diluting buffer (Biomed, Foster City, CA) was used to block nonspecific binding. Fluorescently stained sections were examined under an Olympus Fluoview FV1000 laser-scanning confocal microscope (Olympus, Hamburg, Germany).

Confocal image analysis

Confocal images were generated with a 4-channel Olympus XI81-ZDC confocal microscope (Olympus, Hamburg, Germany) at a 1024 × 1024-pixel resolution with ×10, ×40, or ×60 objectives. To generate 3D images, a z-stack of at least 23 μm thickness, with serial images taken every 0.75 μm, was imaged in the confocal microscope.

3-D reconstruction of individual microglial cells

Z-stack confocal images of 20–40 μm in thickness, taken at intervals of 0.5 μm, were captured from layers 2 and 3 of the cortex (0 to 2 mm lateral to bregma). The images were reconstructed manually with the Filament Tracer plug-in in IMARIS. The backbones of the filaments were generated by selecting the nuclei of the individual microglia. The manual tracing of each process along the z-stack was achieved by selecting points along the midline of the microglial process taking the nucleus as a center, and then allowing the software to find the path and depth between them.

Calculation of morphometric parameters

The following morphometric parameters were calculated using the IMARIS software: (i) total branch length; (ii) number of bifurcations; (iii) tree area. After tracing an individual microglial cell using the Filament Tracer plug-in in IMARIS, the software generates a Microsoft Excel file with statistical values, including the specific thickness
and volume of the cell, as well as its branch length, density, and level. The calculated parameters were then extracted for later analysis with GraphPad Prism

**Total CD4 T cell quantification**

Sections (35 mm thick) were imaged under a confocal microscope and analyzed by using the IMARIS software. The software settings were optimized for identifying only the immunolabeled CD4 T cells. Using the “Surface” option in IMARIS, the CD4+ T cells were defined and, if needed, separated manually. At least four sections were analyzed per brain. The overall number of infiltrating CD4 T cells was quantified mainly in the cortex and hippocampus.

**Measurement of Aβ plaque load and number of MHCII+ cells**

Aβ plaques and MHCII-expressing cells in the brain were quantified in two 35-mm thick sections per hemisphere, stained for Aβ or MHCII. In each section, two regions were used for quantification: the cortex (a block of 1020×1260×15.5 µm; length × width × depth) and the hippocampus (a block of 1260×1260×15.5 µm; length × width × depth). Fluorescence intensity was first obtained in sections from control mice (injected with PBS), and then identical laser-scanning parameters were used for the entire experiment. Using the IMARIS image analysis software, an intensity threshold was set to mark only specific staining. The plaque load in each region was calculated by summatating the volume of plaques (µm³) in each section and dividing it by the volume of the section (µm³). The number of MHCII+ cells was calculated by summatating the number of events in each section and dividing it by the volume of the section. All results were normalized to the control treatment.

**Measurement of Aβ co-localization with microglia**

Sections (35 mm thick) were imaged under a confocal microscope and 3D reconstructions were generated using the Surface plug-in in IMARIS. The 3D
reconstructs were sliced by using a Clipping Plane plug-in in three different axes (XY, YZ, XZ) and oriented in different 3D axes to visualize the co-localization of Aβ with MHCII+/MHCII− cells or with Iba1+ cells. Then, the 3D reconstructions were viewed in IMARISColoc, operated simultaneously on two channels, to measure the degree of overlap between the two channels. The intensity threshold of each channel was calculated by choosing the Automatic Threshold Calculation option. The overlap image was saved as a separated channel, which was then processed by using the Surface plug-in to calculate the volume of Aβ co-localized with MHCII+ and with MHCII− cells or with Iba1+ cells. The degree of Aβ co-localization was calculated by summating the volume of Aβ co-localized with MHCII+ and with MHCII− cells in each section and dividing it by the total volume of Aβ in the section.

**Aβ phagocytic analysis**

Brain sections (35 mm-thick) were immunolabeled for Aβ (red), Iba1(green) and CD68 (blue) and images were taken at intervals of 0.5 μm from layers 2 and 3 of the cortex (0 to 2 mm lateral to bregma). 3D image reconstructions was generated using the Surface plug-in in IMARIS. For co-localization analysis, the 3D reconstructions were viewed in IMARISColoc, which operates on two channels simultaneously to measure the degree of overlap between the channels. The intensity threshold of the different channels was used according to the automatic threshold calculation option. The co-localization images were then saved as separated channels, which were processed using the 3D reconstruction plug-in, and the sum volume of co-localized Aβ out of total volume of Aβ was calculated. At least 3 mice per group (2-3 sections per brain hemisphere) were analyzed.

**T-cell lines**

*Aβ-specific T cell line*
Mice were immunized at 2 m of age by a footpad injection of Aβ1–42 (100 mg; GenScript, Piscataway, NJ) emulsified in CFA H37Ra (Difco, Detroit, MI). The Aβ1–42 peptides used for immunization were initially dissolved in a small volume of DMSO to enhance solubility and then diluted to 2 mg/ml in PBS. The peptide was emulsified with CFA to a final concentration of 1 mg/ml. Ten days later, popliteal, inguinal, and iliac lymph nodes were extracted and the cells were seeded (5×10^6 cells/ml in 24-well culture dish) in an RPMI complete medium (Gibco) supplemented with 20 μg/ml of Aβ1–42. Every other day thereafter, human rIL-2 (20 U/ml) in complete DMEM was added to the solution. After one week and every two weeks later, the T cell cultures were re-stimulated with irradiated (6000 rad) splenocytes and re-seeded at 10^5 T cells/ml, 5 × 10^6 irradiated splenocytes/ml in 24-well plates. To generate Th1 cell subpopulations, we used anti–IL-4 (20 mg/ml, clone: 11B11; BioLegend, San Diego, CA) and mouse IL-12 (20 ng/ml; BioLegend). Recombinant cytokines and cytokine-neutralizing antibodies were supplemented in the first three stimulations during seeding, and then 2 d later.

**Retroviral Transduction of Th1 cells**

The T2A-GFP peptide fusion was cloned into the retroviral vector pMP-71-G-Pre (kindly provided by Prof. Wolfgang Uckert, Max-Delbrück Center for Molecular Medicine). The plasmids were amplified by using Match1 bacteria (Invitrogen, Carlsbad, CA) and purified with a Maxiprep Plasmid DNA Kit (Invitrogen). The packaging cell line Platinum-E (Cell Biolabs, San Diego, CA) was transfected in a 10-cm plate with 20 μg of plasmid DNA and 60 μl of PolyJet™ (SignaGen, Rockville, MD). After 16 h, the medium was replaced with 10 ml of RPMI complete media. After 24 h and again after 48 h, the retrovirus supernatant was collected and filtered through a 0.45-μm filter. Th1 cells were stimulated 48 h at a density of 1×10^6 cells/ml, with
25 µl of anti-CD3/anti-CD28 dynabeads. Next, 1×10⁶ cells/ml of the Th1 cells were spinoculated on RetroNectin-coated plates (12.5 µg/ml; Takara Bio Europe SAS, St. Germain en Laye, France) at 1500 g for 90 min at 32 °C with viral supernatant supplemented with 60 units of IL-2 and 4 µg/ml protamine sulfate (Sigma-Aldrich, St. Louis, MO).

**Cytokine ELISA**

T cells (2×10⁴) and irradiated (6000 rad) APCs (5×10⁵ cells) were cultured in U-shaped 96-well-plate culture dishes in complete RPMI medium with the Aβ1–42 peptides added at increasing concentrations. IL-2 and IL-4 were measured in the supernatant after 24 h; IFN-γ and IL-10 were measured after 48 h; and IL-17A was measured after 72 h, in each case with a sandwich ELISA (BioLegend), according to the manufacturer’s instructions. Samples were analyzed in duplicates.

**Intracerebroventricular injection of CD4 T cells**

CD4+ T cells were restimulated with 25 µl of anti-CD3/anti-CD28 Dynabeads for 36 h and were then harvested and resuspended in PBS at a concentration of 50,000 cells/µl. Mice were anesthetized with isoflurane and 2.5×10⁵ cells were slowly injected over a period of 5 min into each of the lateral ventricles of the brain using a stereotactic device [coordinates relative to bregma: latero-lateral (x) = +1/-1, dorso-ventral (y) = -0.5, rostro-caudal (z) = -2.30].

**Bone marrow adoptive transfer**

Immune-intact ubiquitin GFP (UBC-GFP) mice, age- and sex-matched to the experimental mice, served as donors for BM adoptive transfer. The donor mice were killed by isoflurane, their femurs were removed, and the whole bone marrow was harvested by flushing the marrow contents with PBS. The bone marrow was then
treated with an ammonium-chloride-potassium buffer to lyse red blood cells, filtered through a 70-μm nylon mesh, and the number of cells was counted by a hemocytometer. Recipients mice received three intraperitoneal injections of busulfan (30 mg/g body weight) with 2-day intervals prior to bone marrow transfer. All mice were then treated with antibiotics [Trimethoprim and Sulfamethoxazol (Cotrim-KH)] for 14 days. Each recipient mouse received 500,000 live BM cells in 100 μl of PBS, or an equivalent volume of PBS in control mice, though an intravenous injection. Successful engraftment (more than 98% of GFP+Ly6C+CD45+ monocytes) was confirmed by flow-cytometric analysis of blood taken after 6 weeks.

Flow cytometry
Mice were sacrificed via isoflurane inhalation, quickly perfused, and their brains were collected in cold PBS. The mononuclear single-cell suspension was prepared according to standard protocols (Ferretti et al., 2016; Suter et al., 2003) The whole brain was minced and digested for 1 h at 37 °C in HBSS containing 50 μg/ml DNase I and 100 μg/ml collagenase/dispase (Roche, Rotkreuz, Switzerland). The suspension was passed through a 70-μm Nylon mesh (Falcon, BD Biosciences, Bedford, MA), pelleted, resuspended in 30% Percoll (GE Healthcare Bio-science, USA) in HBSS and centrifuged at 15,500 rpm for 30 min at 4 °C. After eliminating the myelin debris via aspiration, the mononuclear cell phase was collected. CNS-monoruclear cells were washed in a flow cytometry buffer (HBSS, 2% FCS, 10 mM EDTA). After treatment with an antibody against the Fc receptor (anti-mouse CD16/32, TrueStain FcX TM, BioLegend, San Diego, CA), the cells were stained for 15 min at 4 °C with specific antibodies, washed, and analyzed. A multicolor flow cytometry study was performed with a cytoflex.

Fluorescent in situ hybridization (FISH)
FISH detection of transcripts was performed using the RNAscope technology (Advanced Cell Diagnostics, Newark, NJ) according to the manufacturer’s instructions. Target probes were purchased from the available probe catalog. The manufacturer’s standard multiplex fluorescent protocols were used for freshly frozen mouse brain sections. Coverslips or sections were mounted with DAPI Fluoromount-G (Southern Biotech, Birmingham, AL) to visualize nuclei. Probes used in the current study included Mm CD74 (Cat No. 437501-C2), Mm P2ry12 (Cat No. 317601-C3), Mm RNAscope® 3-plex positive control probe (Cat No. 320881), and Mm RNAscope® 3-plex Negative Control Probe (Cat No. 320871).

**Antibodies**

**Immunohistochemistry**

Purified rat anti-CD4 (1:100) and rat anti-MHCII (1:100) were purchased from BioLegend. Rabbit anti-mouse Iba-1 (1:1000) was purchased from Wako (Osaka, Japan). Rabbit anti-Zap70 (phosphor Tyr 319) (1:100) was purchased from GeneTex (USA). CF® dye phalloidin (CF633) was purchased from Biotium. Rabbit anti-human Aβ antibodies (1:250) were generated at our animal facility and examined for specificity by ELISA and IHC. Alexa 488, 546, or 633 antibodies (Invitrogen), diluted to 1:250–500, were used for secondary staining. TOPRO-3 (Invitrogen), diluted 1:3000, was used for counterstaining.

**Flow cytometry**

Anti-CX3CR1 (PE), anti-CD11c (PE-dazzle 594), anti-CD45.1 (APC), anti-I-A/I-E (MHC II, AF 700), anti-CD45.2 (APC-cy7), anti-CD11b (BV 421), anti-CD4 (BV 510), anti-CD11b (BV605), anti-CD45.2 (BV660), and anti-CX3CR1 (BV785) were purchased from Biolegend; anti-Claudin-1 (AF 488) was purchased from Bioss.
(Wobam, MA); and anti-CD54 (ICAM-1, PE-vio-770) was purchased from Miltenyi Biotech (Bergisch Gladbach, Germany).

**Quantitative PCR**

Mice were anesthetized with isoflurane, perfused with PBS, and half brains were immediately frozen in liquid nitrogen and stored at -80 °C. RNA was extracted by a phenol-chloroform procedure and analyzed by using Bioanalyzer (Molecular Research Center, Cincinnati, OH). A total of 2 μg RNA was reverse-transcribed with a high-capacity cDNA reverse-transcription kit (Applied Biosystems, Foster City, CA) and 25 ng of cDNA were used for the qPCR analysis. The CXCL9, CXCL10, CXCL11, INF-γ, CD74, and CCL2 genes were analyzed with TaqMan Gene Expression Assay (Applied Biosystems) with GAPDH as an endogenous control.

**Statistical analyses**

All statistical analyses were conducted using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA). All variables are expressed as means ± SEM or SD, as indicated in figure legends. The p values were calculated with a one-way ANOVA or t-tests, as indicated in the figure legends.
References

Ferretti, M.T., Merlini, M., Spani, C., Gericke, C., Schweizer, N., Enzmann, G., Engelhardt, B., Kulic, L., Suter, T., and Nitsch, R.M. (2016). T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis. Brain Behav Immun 54, 211-225.

Madsen, L., Labrecque, N., Engberg, J., Dierich, A., Svejgaard, A., Benoist, C., Mathis, D., and Fugger, L. (1999). Mice lacking all conventional MHC class II genes. Proceedings of the National Academy of Sciences 96, 10338-10343.

Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.

Suter, T., Biollaz, G., Gatto, D., Bernasconi, L., Herren, T., Reith, W., and Fontana, A. (2003). The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol 33, 2998-3006.